Support and Resistance Basics
What is MACD and how to read it?
How RSI can help?
Stock Summary
Top Correlated Resources
OMER
Top 10 Correlated ETFs
OMER
Top 10 Correlated Stocks
OMER
In the News
Omeros Corporation (OMER) CEO Gregory Demopulos on Q2 2022 Results - Earnings Call Transcript
Omeros Corporation. (NASDAQ:OMER ) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Jennifer Williams - Investor Relations Gregory Demopulos - Chairman & Chief Executive Officer Mike Jacobsen - Chief Accounting Officer Cathy Melfi - Chief Regulatory Officer Steve Whitaker - Chief Clinical Officer Nadia Dac - Chief Commercial Officer Conference Call Participants Greg Harrison - Bank of America Steve Brozak - WBB Hannah Adeoye - JPMorgan Brandon Folkes - Cantor Fitzgerald Operator Good afternoon and welcome to today's earnings call for Omeros Corporation.
Why Omeros Corporation Stock Is Marching Higher Today
A positive regulatory development is powering the biotech's shares higher today.
Why Omeros Stock Is Freefalling Today
It's reverting to where it was before its massive uptick last week.
Omeros: On Death's Door
Omeros shareholders have watched with dismay as its share price languishes ever lower. Omeros' $200 million OMIDRIA milestone is cloaked in uncertainty.
Omeros Corporation (OMER) CEO Greg Demopulos on Q1 2022 Results - Earnings Call Transcript
Omeros Corporation (NASDAQ:OMER ) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Jennifer Williams - Investor Relations Greg Demopulos - Chairman & Chief Executive Officer Mike Jacobsen - Chief Accounting Officer Cathy Melfi - Chief Regulatory Officer Steve Whitaker - Chief Clinical Officer Conference Call Participants Eric Joseph - JPMorgan Greg Harrison - Bank of America Brandon Folkes - Cantor Fitzgerald Operator Good afternoon and welcome to today's earnings call for Omeros Corporation. At this time, all participants are in a listen-only mode.
Omeros: The Weight Of The Wait, A Conundrum
Omeros' OMIDRIA sale has substantially improved its financial prospects. Omeros' CRL gangplank is agonizing for shareholders as they wait for FDA response to its type A meeting.
Omeros Corporation's (OMER) CEO Greg Demopulos on Q4 2021 Results - Earnings Call Transcript
Omeros Corporation's (OMER) CEO Greg Demopulos on Q4 2021 Results - Earnings Call Transcript
Why Earnings Season Could Be Great for Omeros (OMER)
Omeros (OMER) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Omeros: Despite Its Promise, The CRL Is A Huge Obstacle
Omeros was handed a CRL for narsoplimab. The lack of clarity surrounding the CRL is disconcerting.
Omeros Submits Response To FDA Regarding Narsoplimab Application In HSCT-TMA
Omeros Corporation (NASDAQ: OMER) has submitted to the FDA its response to Complete Response Letter for narsoplimab in hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). The response comprises a comprehensive briefing package drafted in close collaboration with external clinical, regulatory, and legal experts addressing the points raised by the FDA.
Financial details
Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 1.42 | 0.61 | 2.26 | 1.29 | 0 | |
| Net income per share | -1.17 | -2.61 | -1.71 | -2.41 | 3.12 | |
| Operating cash flow per share | -0.8 | -2.14 | -1.21 | -1.75 | -1.76 | |
| Free cash flow per share | -0.8 | -2.15 | -1.22 | -1.76 | -1.76 | |
| Cash per share | 1.84 | 1.25 | 1.23 | 2.36 | 2.52 | |
| Book value per share | -0.06 | -2.06 | -2.2 | -2.11 | 0.38 | |
| Tangible book value per share | -0.06 | -2.06 | -2.2 | -2.11 | 0.38 | |
| Share holders equity per share | -0.06 | -2.06 | -2.2 | -2.11 | 0.38 | |
| Interest debt per share | 2.07 | 3.4 | 3.65 | 4.6 | 5.89 | |
| Market cap | 755.04M | 635.95M | 646.78M | 1.11B | 351M | |
| Enterprise value | 834.96M | 779.07M | 801.91M | 1.34B | 598.03M | |
| P/E ratio | -14.12 | -5.02 | -7.66 | -8.06 | 1.81 | |
| Price to sales ratio | 11.65 | 21.29 | 5.78 | 15.07 | 0 | |
| POCF ratio | -20.84 | -6.13 | -10.77 | -11.12 | -3.2 | |
| PFCF ratio | -20.64 | -6.1 | -10.71 | -11.09 | -3.19 | |
| P/B Ratio | -268.32 | -6.35 | -5.93 | -9.21 | 14.76 | |
| PTB ratio | -268.32 | -6.35 | -5.93 | -9.21 | 14.76 | |
| EV to sales | 12.88 | 26.08 | 7.17 | 18.13 | 0 | |
| Enterprise value over EBITDA | -19.93 | -6.36 | -13.36 | -11 | -3.51 | |
| EV to operating cash flow | -23.05 | -7.51 | -13.35 | -13.37 | -5.45 | |
| EV to free cash flow | -22.83 | -7.47 | -13.28 | -13.34 | -5.44 | |
| Earnings yield | -0.07 | -0.2 | -0.13 | -0.12 | 0.55 | |
| Free cash flow yield | -0.05 | -0.16 | -0.09 | -0.09 | -0.31 | |
| Debt to equity | -29.6 | -1.49 | -1.45 | -1.96 | 14.41 | |
| Debt to assets | 1.02 | 2.04 | 1.8 | 1.67 | 0.94 | |
| Net debt to EBITDA | -1.91 | -1.17 | -2.58 | -1.86 | -1.45 | |
| Current ratio | 4.12 | 2.41 | 1.87 | 4.12 | 4.79 | |
| Interest coverage | -3.98 | -6.91 | -2.8 | -4.13 | -8.83 | |
| Income quality | 0.68 | 0.82 | 0.71 | 0.72 | -0.56 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.8 | 1.73 | 0.58 | 0.98 | 0 | |
| Research and developement to revenue | 0.86 | 3.01 | 0.98 | 1.5 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.01 | 0.01 | 0.01 | 0 | 0 | |
| Capex to revenue | -0.01 | -0.02 | 0 | 0 | 0 | |
| Capex to depreciation | -0.64 | -0.59 | -0.19 | -0.18 | -0.2 | |
| Stock based compensation to revenue | 0.2 | 0.39 | 0.12 | 0.2 | 0 | |
| Graham number | 1.28 | 11 | 9.19 | 10.71 | 5.17 | |
| ROIC | -0.49 | -1.92 | -0.78 | -0.77 | -0.47 | |
| Return on tangible assets | -0.46 | -1.32 | -0.62 | -0.76 | 0.46 | |
| Graham Net | -0.49 | -2.44 | -3.2 | -2.86 | -2.83 | |
| Working capital | 82.07M | 52.51M | 48.29M | 114.55M | 196.1M | |
| Tangible asset value | 0 | 0 | 0 | 0 | 0 | |
| Net current asset value | -10.77M | -106.23M | -142.25M | -150.51M | -147.6M | |
| Invested capital | -29.6 | -1.49 | -1.45 | -1.96 | 14.63 | |
| Average receivables | 10.49M | 13.33M | 19.51M | 3.84M | 43.16M | |
| Average payables | 5.45M | 5.24M | 4.76M | 4.2M | 8.8M | |
| Average inventory | 899K | 721.5K | 1.25M | 1.36M | 0 | |
| Days sales outstanding | 96.53 | 278.85 | 114.87 | 18.99 | 0 | |
| Days payables outstanding | 2.27K | 4.48K | 2.25K | 1.7K | 0 | |
| Days of inventory on hand | 150 | 62.73 | 483.99 | 548.31 | 0 | |
| Receivables turnover | 3.78 | 1.31 | 3.18 | 19.22 | 0 | |
| Payables turnover | 0.16 | 0.08 | 0.16 | 0.21 | 0 | |
| Inventory turnover | 2.43 | 5.82 | 0.75 | 0.67 | 0 | |
| ROE | 19.01 | 1.27 | 0.77 | 1.14 | 8.17 | |
| Capex per share | -0.01 | -0.01 | -0.01 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2022-03-31 for Q1
| Metric | History | 2021-03-31 | 2021-06-30 | 2021-09-30 | 2021-12-31 | 2022-03-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 0.34 | 0.46 | 0.48 | -1.28 | 0 | |
| Net income per share | -0.57 | -0.46 | -0.36 | 4.49 | -0.53 | |
| Operating cash flow per share | -0.65 | -0.44 | -0.38 | -0.29 | -0.24 | |
| Free cash flow per share | -0.65 | -0.44 | -0.38 | -0.29 | -0.24 | |
| Cash per share | 1.62 | 1.18 | 0.81 | 2.51 | 2.27 | |
| Book value per share | -3.58 | -3.95 | -4.2 | 0.38 | -0.08 | |
| Tangible book value per share | -3.58 | -3.95 | -4.2 | 0.38 | -0.08 | |
| Share holders equity per share | -3.58 | -3.95 | -4.2 | 0.38 | -0.08 | |
| Interest debt per share | 5.63 | 5.67 | 5.65 | 5.64 | 5.53 | |
| Market cap | 1.1B | 925.62M | 862.02M | 402.21M | 376.98M | |
| Enterprise value | 1.44B | 1.26B | 1.2B | 649.24M | 710.14M | |
| P/E ratio | -7.85 | -8.09 | -9.49 | 0.36 | -2.85 | |
| Price to sales ratio | 52.34 | 32.11 | 28.73 | -5.03 | 0 | |
| POCF ratio | -27.38 | -33.55 | -36.43 | -22.08 | -24.81 | |
| PFCF ratio | -27.38 | -33.44 | -36.27 | -21.99 | -24.81 | |
| P/B Ratio | -4.97 | -3.76 | -3.28 | 16.91 | -76.54 | |
| PTB ratio | -4.97 | -3.76 | -3.28 | 16.91 | -76.54 | |
| EV to sales | 68.23 | 43.78 | 40.09 | -8.13 | 0 | |
| Enterprise value over EBITDA | -48.22 | -54.09 | -68.84 | 2.27 | -20.72 | |
| EV to operating cash flow | -35.7 | -45.73 | -50.84 | -35.64 | -46.74 | |
| EV to free cash flow | -35.69 | -45.58 | -50.62 | -35.5 | -46.74 | |
| Earnings yield | -0.03 | -0.03 | -0.03 | 0.7 | -0.09 | |
| Free cash flow yield | -0.04 | -0.03 | -0.03 | -0.05 | -0.04 | |
| Debt to equity | -1.53 | -1.4 | -1.31 | 14.41 | -68.67 | |
| Debt to assets | 2.37 | 2.69 | 3.13 | 0.94 | 1.01 | |
| Net debt to EBITDA | -11.23 | -14.41 | -19.51 | 0.86 | -9.72 | |
| Current ratio | 3.05 | 2.36 | 2.13 | 4.79 | 6 | |
| Interest coverage | -6.25 | -4.89 | -3.72 | -20.35 | -7.09 | |
| Income quality | 1.15 | 0.96 | 1.04 | -0.06 | 0.46 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.86 | 0.75 | 0.7 | 0.07 | 0 | |
| Research and developement to revenue | 1.58 | 1.07 | 0.9 | -0.34 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -0.03 | -0.25 | -0.32 | -0.23 | 0 | |
| Stock based compensation to revenue | 0.16 | 0.11 | 0.19 | -0.07 | 0 | |
| Graham number | 6.76 | 6.38 | 5.86 | 6.19 | 0.96 | |
| ROIC | -0.26 | -0.25 | -0.23 | -0.27 | -0.1 | |
| Return on tangible assets | -0.22 | -0.2 | -0.18 | 0.67 | -0.09 | |
| Graham Net | -4.26 | -4.71 | -4.96 | -2.82 | -2.98 | |
| Working capital | 89.05M | 64.7M | 48.53M | 196.1M | 175.16M | |
| Tangible asset value | 0 | 0 | 0 | 0 | 0 | |
| Net current asset value | -250.92M | -279.29M | -294.78M | -147.6M | -163.97M | |
| Invested capital | -1.55 | -1.42 | -1.33 | 14.63 | -69.47 | |
| Average receivables | 53.65M | 57.16M | 58.19M | 82.47M | 71.42M | |
| Average payables | 12.45M | 11.45M | 11.71M | 13.4M | 10.37M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 106.09 | 99.41 | 101.68 | -92.91 | 0 | |
| Days payables outstanding | 3.94K | 2.5K | 2.71K | -1.29K | 0 | |
| Days of inventory on hand | 407.57 | 257.37 | 192.43 | 0 | 0 | |
| Receivables turnover | 0.85 | 0.91 | 0.89 | -0.97 | 0 | |
| Payables turnover | 0.02 | 0.04 | 0.03 | -0.07 | 0 | |
| Inventory turnover | 0.22 | 0.35 | 0.47 | 0 | 0 | |
| ROE | 0.16 | 0.12 | 0.09 | 11.8 | 6.7 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
Company Profile
- Volume Average 1.52M
- Market Capitalization 456.77M
- Employee 213
- CEO Dr. Gregory Demopulos
- Headquarters Seattle,WASHINGTON,US
- IPO Date 2009-10-08
-
Website
https://www.omeros.com 
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.
